What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the PipelineThe Motley Fool • 02/05/20
Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock?Zacks Investment Research • 01/10/20
Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and PatientsThe Motley Fool • 01/09/20
Best Stocks for 2020: Aimmune’s Allergy Solutions Position It for Huge SuccessInvestorPlace • 12/23/19
Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/07/19
Aimmune: FDA Panel Nod Pushes Peanut Allergy Treatment One Step Closer To Potential ApprovalSeeking Alpha • 09/25/19